Leadership Overview
Medicilon has 5 executives leading key functions including strategy, technology, operations, revenue, and corporate development.
Committed to advancing global human health through comprehensive drug discovery research, Medicilon delivers high-quality preclinical development and bioanalytical support to pharmaceutical partners worldwide.
Committed to advancing global human health through comprehensive drug discovery research, Medicilon delivers high-quality preclinical development and bioanalytical support to pharmaceutical partners worldwide.
Leadership Roles at Medicilon
Chun Chen - Chief Executive Officer
Chun Chen, the Chief Executive Officer at Medicilon, directs the overarching strategic vision for this professional drug discovery contract research organization. By aligning medicinal chemistry and preclinical development capabilities with global market demands, the Chief Executive Officer ensures consistent growth across the entire service portfolio. Chun Chen maintains rigorous oversight of the organization's expansion into international biotechnology sectors, fostering innovation within the drug research lifecycle. This leadership role involves constant collaboration with the Board to refine long-term objectives and maintain the company's competitive edge in the pharmaceutical research landscape. Through the optimization of internal processes and the cultivation of strategic partnerships, the Chief Executive Officer drives the delivery of high-value research services to over 900 clients. Ultimately, the Chief Executive Officer secures the financial and operational health of the firm while advancing the mission of improving global health outcomes.
Guolin Wang - Chief Operating Officer
Guolin Wang, the Chief Operating Officer at Medicilon, manages the daily operational execution of drug discovery and preclinical research services. By streamlining workflows across process chemistry and bioanalytical support departments, the Chief Operating Officer ensures maximum efficiency in project delivery. Guolin Wang coordinates cross-functional teams to maintain strict adherence to quality standards and project timelines for global pharmaceutical clients. This leadership position involves optimizing resource allocation and scaling operational capacity to meet the increasing demand for contract research services. Through the implementation of robust operational policies, the Chief Operating Officer supports the company's mission of delivering high-quality research solutions. The Chief Operating Officer also monitors performance metrics to identify areas for process improvement, ensuring that the organization remains agile in a competitive market. Ultimately, the Chief Operating Officer drives the operational excellence required to sustain the company's growth and reputation in the global biotechnology sector.
Qingcong Lin - President, Medicilon Corporate (USA) & Executive VP, Shanghai Medicilon Inc
Qingcong Lin, the President, Medicilon Corporate (USA) & Executive VP, Shanghai Medicilon Inc at Medicilon, directs the company's North American operations and coordinates executive functions between international branches. By bridging the gap between the organization's global headquarters and the United States market, the President, Medicilon Corporate (USA) & Executive VP, Shanghai Medicilon Inc ensures seamless service delivery for international clients. Qingcong Lin oversees the expansion of the company's footprint in the Western market, focusing on building strong relationships with biotechnology firms and pharmaceutical innovators. This leadership role involves aligning regional business strategies with the overarching corporate mission of advancing drug discovery. Through the management of cross-border collaborations, the President, Medicilon Corporate (USA) & Executive VP, Shanghai Medicilon Inc enhances the company's global reach and operational synergy. By fostering a culture of excellence and scientific rigor, the President, Medicilon Corporate (USA) & Executive VP, Shanghai Medicilon Inc drives the company's continued success in the competitive global CRO landscape.

Lily Xu - Chief Technology Officer
Lily Xu, the Chief Technology Officer at Medicilon, architects the technical framework for advanced drug discovery and pharmaceutical research services. Overseeing the integration of in vitro and in vivo DMPK methodologies, the Chief Technology Officer ensures that all laboratory operations meet the highest standards of scientific precision. Lily Xu drives the implementation of cutting-edge research technologies to support complex medicinal chemistry projects and bioanalytical requirements. This role involves constant evaluation of emerging scientific trends to maintain the organization's position at the forefront of the contract research industry. By managing the technical infrastructure and scientific talent, the Chief Technology Officer facilitates the seamless execution of preclinical development programs for a diverse global client base. Through the continuous refinement of research protocols, the Chief Technology Officer enhances the efficiency and reliability of the company's service offerings, directly contributing to the success of client drug development pipelines.
Donghui Yu - Chief Revenue Officer, Preclinical Business Development & Specialist
Donghui Yu, the Chief Revenue Officer, Preclinical Business Development & Specialist at Medicilon, drives the commercial strategy and revenue growth for the company's preclinical service lines. By identifying new market opportunities and expanding the client base, the Chief Revenue Officer, Preclinical Business Development & Specialist ensures the sustained financial performance of the organization. Donghui Yu manages high-level relationships with pharmaceutical and biotechnology partners, tailoring service packages to meet specific drug discovery needs. This role involves analyzing market trends to position the company's preclinical development and bioanalytical capabilities effectively against global competitors. Through the development of strategic sales initiatives, the Chief Revenue Officer, Preclinical Business Development & Specialist facilitates the acquisition of new projects and the retention of existing accounts. By aligning business development efforts with the company's research strengths, the Chief Revenue Officer, Preclinical Business Development & Specialist secures the necessary revenue to support ongoing innovation and infrastructure investment.
Explore Leadership Teams in Business Services
NORC at the University of Chicago is a nonpartisan research organization that provides objective insights and analysis to inform decision-makers. The organization conducts extensive research across various fields, including economics, education, health, and public affairs. NORC offers a range of services, including research design, data collection, and analytics, to meet the needs of its clients. Its intended clients include government agencies, non-profit organizations, and other entities seeking reliable data and evaluation support.
Company Leadership
EB

Discovery Life Sciences is dedicated to accelerating breakthroughs in precision medicine by providing high-quality biospecimens, preclinical products, and specialty lab services. Their offerings include multi-omic technologies across genomics, proteomics, molecular pathology, and cell biology, tailored to support biopharma, clinical diagnostics, and academic research. The company aims to enhance the capabilities of its clients, enabling them to improve patient outcomes through innovative diagnostics and effective treatments. With a global presence and a commitment to quality, Discovery Life Sciences serves as a strategic partner for organizations in the biopharmaceutical and clinical research sectors.
Company Leadership GH
SH

WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs and advanced therapies in the People's Republic of China, the United States, Europe, and internationally. The company operates in six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic.
Company Leadership HH


XL
Cytek Biosciences is a leading cell analysis solutions company founded in 1992 and headquartered in Fremont, California with global offices across North America, Europe, and Asia. The company specializes in research and development of advanced cell analysis tools through its patented Full Spectrum Profiling technology. Cytek's product portfolio includes scientific instruments such as the Aurora and Northern Lights systems, cell sorters, reagents, and supporting software that enable high-resolution and high-sensitivity cell analysis for research purposes. The company provides comprehensive solutions for scientific research institutions and laboratories, with its Northern Lights CLC system available for clinical use in China and the European Union. Cytek Biosciences operates in the biotechnology and scientific research services sector, offering both business-to-business and business-to-consumer products through its website cytekbio.com and other distribution channels.
Company Leadership

IF
MY